Typhoid Fever Pipeline Review, H2 Global Share and Size, Trends and Growth, Segment Forecast to 2015

1. Hexa Reports Market Research Reports and Insightful Company Profiles Typhoid Fever Industry 2015 Market Share, Size, Industry Profile, Market Prize, Forecast and Overview Global Markets Direct's, 'Typhoid Fever - Pipeline Review, H2 2015', provides an overview of the Typhoid Fever's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Typhoid Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Typhoid Fever and special features on late-stage and discontinued projects. Browse Detail Report With TOC @ http://www.hexareports.com/report/typhoid-fever-pipeline- review-h2-2015/details Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

2. Hexa Reports Market Research Reports and Insightful Company Profiles The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides a snapshot of the global therapeutic landscape of Primary Typhoid Fever The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Primary Typhoid Feverand enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Primary Typhoid Feverproducts under development by companies and universities/research institutes based on information derived from company and industry specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Primary Typhoid Feverpipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Primary Typhoid Fever Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Primary Typhoid Feverpipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

3. Hexa Reports Market Research Reports and Insightful Company Profiles Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Request A Sample copy of This Report @ http://www.hexareports.com/sample/46607 Table Of Content List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Typhoid Fever Overview 7 Therapeutics Development 8 Pipeline Products for Typhoid Fever - Overview 8 Pipeline Products for Typhoid Fever - Comparative Analysis 9 Typhoid Fever - Therapeutics under Development by Companies 10 Typhoid Fever - Therapeutics under Investigation by Universities/Institutes 11 Typhoid Fever - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Typhoid Fever - Products under Development by Companies 15 Typhoid Fever - Products under Investigation by Universities/Institutes 16 Typhoid Fever - Companies Involved in Therapeutics Development 17 Chongqing Zhifei Biological Products Co., Ltd. 17 GlaxoSmithKline Plc 18 Prokarium Limited 19 Protein Potential, LLC 20 Shantha Biotechnics Limited 21 USV Limited 22 Zydus Cadila Healthcare Limited 23 Typhoid Fever - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Combination Products 25 Assessment by Target 26 Assessment by Route of Administration 28 Assessment by Molecule Type 29 Drug Profiles 31 (typhoid fever + shigellosis) multivalent vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Typhella - Drug Profile 32

4. Hexa Reports Market Research Reports and Insightful Company Profiles Product Description 32 Mechanism of Action 32 R&D Progress 32 Typhetec - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 typhoid + paratyphoid (bivalent) vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 typhoid + paratyphoid vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 typhoid + pneumococcal vaccine - Drug Profile 37 Browse Full Report @http://www.hexareports.com/report/typhoid-fever-pipeline-review-h2- 2015/details About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/